Quantcast

Latest Antiretroviral drug Stories

2014-08-22 16:23:16

LONDON, Aug. 22, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside...

2014-08-19 08:29:32

VANCOUVER, Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with...

2014-08-05 16:27:17

A man infected by HIV-1 in 1998 was treated at the time of acute infection with 4 antiretrovirals during 2 years and is now still in remission TOULON, France, Aug. 5, 2014 /PRNewswire/ -- There is only one man cured from HIV in the world, the "Berlin" patient: the only case of HIV cure, because in every infected patient we observe a HIV persistence. To reach this cure he received a non-scalable procedure with bone marrow transplant due to acute leukemia from a special donor. His life...

2014-08-05 11:54:33

BMJ-British Medical Journal Antiretroviral drugs and chronic immune system suppression might explain link HIV infection is linked to a significantly lower risk of developing multiple sclerosis (MS), indicates observational research published online in the Journal of Neurology Neurosurgery & Psychiatry. Chronic dampening down of the immune system as a result of the infection and/or the antiretroviral drugs used to treat it might explain this association, say the researchers....

2014-07-25 09:45:29

University of Cincinnati Academic Health Center Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication, according to a new study lead by a University of Cincinnati researcher. The results were published Wednesday, July 23, 2014, in Science Translational Medicine. Previously, physicians treating co-infected patients worried that HIV antiretroviral therapy might injure the liver...

2014-07-24 10:43:07

Temple University Health System Their approach promises a permanent cure and potential for protection against HIV The HIV-1 virus has proved to be tenacious, inserting its genome permanently into its victims' DNA, forcing patients to take a lifelong drug regimen to control the virus and prevent a fresh attack. Now, a team of Temple University School of Medicine researchers has designed a way to snip out the integrated HIV-1 genes for good. "This is one important step on the path...

2014-07-24 00:21:34

MELBOURNE, Australia, July 24, 2014 /PRNewswire/ -- Announced at the 20th International AIDS Conference in Melbourne, the agreement seeks to increase access to a promising new HIV medicine in 112 developing countries At the AIDS 2014 conference in Melbourne today, the Medicines Patent Pool (MPP) announced a new licensing agreement with Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine currently...

2014-07-22 04:21:22

- iPrEx OLE is the first PrEP demonstration project to report on its experience; results presented as a late-breaker at AIDS 2014, published in Lancet Infectious Diseases - MELBOURNE, Australia, July 22, 2014 /PRNewswire-USNewswire/ -- Oral HIV pre-exposure prophylaxis (PrEP) provides a high degree of protection against HIV infection, even for individuals who miss some daily doses, according to new data from iPrEx OLE, the first PrEP demonstration project to report outcomes. PrEP was...

2014-07-21 11:19:15

The JAMA Network Journals Among heterosexual African couples in which the male was HIV positive and the female was not, receipt of antiretroviral pre-exposure preventive (PrEP) therapy did not result in significant differences in pregnancy incidence, birth outcomes, and infant growth compared to females who received placebo, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The authors note that these findings do not provide a definitive conclusion regarding...

2014-07-21 11:08:54

The JAMA Network Journals Among adults in the African country of Malawi offered HIV self-testing, optional home initiation of care compared with standard HIV care resulted in a significant increase in the proportion of adults initiating antiretroviral therapy, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The issue is being released early to coincide with the International AIDS Conference. In 2012, an estimated 35 million individuals were infected...


Latest Antiretroviral drug Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »
Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related